AnaBios News


CEO Message: Critical Research Needed to Fight the Coronavirus Pandemic

These challenging times call for united social and corporate responsibilities, as well as meaningful actions, that can help mitigate and, ultimately, overcome the coronavirus global pandemic. As an innovative biotechnology company, AnaBios is focused on how drugs work in humans to treat and prevent diseases. The first critical step in tackling a disease is to understand how it develops in humans. For Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which causes COVID-19, the scientific insight is rapidly advancing as a result of significant effort by clinicians and scientists across the globe. Nonetheless, there remains a tremendous level of uncertainty about the [...]

March 23rd, 2020|

AnaBios to Develop Drug Screening Assays Based on Human Spinal Cord Tissue

SAN DIEGO, CA – March 10, 2020 – Today, AnaBios announced a collaboration with Eli Lilly and Company (Lilly) to develop proprietary electrophysiology assays for preclinical drug discovery research. The collaboration will leverage AnaBios’ expertise in the recovery and interrogation of human cell and tissue samples. The project will focus on ethically-consented samples of human spinal cord and provide an unprecedented preclinical paradigm for studying how new drug candidates can modulate the transmission of sensory and motor information between the brain and peripheral tissues. “AnaBios is excited to work with Lilly to develop these new human central nervous system [...]

March 10th, 2020|

FDA Inks Research Collaboration Agreement with AnaBios Focused on Human Primary Cardiomyocytes

SAN DIEGO, CA – March 10, 2020 – Today, AnaBios announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) to study adult human primary cardiomyocytes as a reference for cellular properties and drug-induced effects on cardiac function. Under the RCA, the FDA Center for Drug Evaluation and Research (CDER) and AnaBios will evaluate functional human primary cardiomyocytes as standards for reference of gene expression, localization of functional proteins and sensitivity of their functional properties to inotropic drugs, i.e. those that affect the strength of cardiomyocyte contractility. “AnaBios is pleased to collaborate with the FDA at [...]

March 9th, 2020|

AnaBios CEO Interviewed by Legal Drugs Podcast

AnaBios CEO Dr. Andre Ghetti was recently interviewed by Angela Stoyanovitch, host of the Legal Drugs Podcast. They discussed the challenges of overcoming animal model data. Dr. Ghetti discusses case studies that demonstrate the need for relevant, predictive data at the preclinical drug discovery stage to better guide decision-making processes. He also discusses the challenges AnaBios has overcome, as well as future challenges Listen to the full podcast here.

January 7th, 2020|

FDA Awards AnaBios Contract to Obtain Critical Translational Data from Ex Vivo Human Cardiac Platform

SAN DIEGO, CA – November 5, 2019 – The U.S. Food and Drug Administration (FDA) has awarded AnaBios an exclusive Indefinite Delivery Indefinite Quantity (IDIQ) contract to employ adult human primary tissues and cardiomyocytes from organ donors to assess drug safety related to cardiac function. “AnaBios is very honored to receive this contract from the FDA for this important project related to the cardiac safety assessment of drugs,” said Dr. Paul E. Miller, co-founder and Chief Corporate Development Officer of AnaBios. “For over a decade, AnaBios has worked diligently to develop a translational ex-vivo human heart platform. We anticipate [...]

November 4th, 2019|

AnaBios Wins NCATS ASPIRE Award to Further Develop Preclinical Pain Assays Using Human Sensory Neurons

SAN DIEGO, CA – September 25, 2019 – The National Center for Advancing Translational Sciences (NCATS) awarded AnaBios the ASPIRE Design Challenge award in the category entitled, “Biological Assays for Translational Innovation in Pain, Opioid Use Disorder and Overdose.” Funds from the award will be used to study ex vivo human models of pain for translational drug discovery. “AnaBios is honored to receive this recognition from NCATS for providing important innovations in preclinical pain research,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “We appreciate the recognition from the Helping to End Addiction Long-term (HEAL) Initiative and are [...]

September 25th, 2019|

FDA Awards AnaBios Grant to Further Develop Preclinical Assay Using Human Primary Cardiomyocytes

SAN DIEGO, CA – September 17, 2019 – The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).  Funds from the grant will be used to develop a preclinical biomarker to identify the pro-arrhythmia risk of potential drugs based on contractility measurements in human adult primary cardiomyocytes. AnaBios’ cardiomyocyte research has yielded highly translational information about cellular properties and drug-induced variations in cardiac function. “AnaBios is honored to receive this grant from the FDA for this [...]

September 16th, 2019|

AnaBios Provides Human Tissue Samples to NCATS for Pain Research

SAN DIEGO, CA – August 13, 2019 – AnaBios Corp. today announced it is providing validated human dorsal root ganglion (hDRG) to the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), for research collaborations to develop human cell-based screening platforms and novel drugs to treat pain and opioid use disorder. The collaborations are part of the NIH HEAL (Helping End Addiction Long-term) Initiative. Dorsal root ganglion neurons are surgically recovered by AnaBios from ethically consented organ donors. These tissue samples from the peripheral nervous system comprise the human sensory neurons that [...]

August 13th, 2019|

San Diego Company Developing Non Opioid Pain Treatment

SAN DIEGO, CA – October 5, 2018 – A San Diego based bio tech company is developing a non opioid procedure to treat chronic pain. Dr. Andrew Ghetti is the CEO at AnaBios Corporation , which is the first in the world to use human neurons for advancing pain drugs. He tells KOGO news models with rats and mice don't usually work. He says drugs that seem to do wonders in animals are completely ineffective or outright toxic in humans AnaBios' approach is to treat the nerve paths with a series of drugs targeting molecules in the body called [...]

October 12th, 2018|

AnaBios to Announce Clinical Candidates for Chronic Pain at IASP World Congress on Pain

SAN DIEGO, CA – August 28, 2018 – AnaBios, the leader in translational pain research, will present its clinical candidates for the treatment of chronic pain at the 17th IASP World Congress on Pain on September 12 in Boston, Mass. The molecules—part of AnaBios’ advanced internal drug discovery program—have a novel selectivity profile and properties, targeting ion channels highly expressed in pathological states associated with pain. “We are very encouraged by the results obtained thus far from these novel compounds and believe they present a significant opportunity for developing non-opioid therapeutics to treat chronic pain,” said Dr. Andre Ghetti, [...]

August 28th, 2018|

AnaBios Announces the Hire of Dr. Chris Mathes as Chief Commercial Officer

SAN DIEGO, CA – May 22, 2018 – AnaBios is pleased to announce the recent hire of Chris Mathes, Ph.D., MBA, as Chief Commercial Officer. Within this new role, Mathes will guide the company’s business development endeavors and contribute to AnaBios’ overall strategic direction as it leverages its proven drug de-risking technology based on ex vivo human pharmacological responses. Mathes joins AnaBios from early drug discovery company Icagen, where he was Chief Commercial Officer. Prior to that, he served as Chief Commercial Officer at ChanTest, now part of Charles River, and headed up North American business development activities for [...]

May 21st, 2018|

AnaBios Announces Agreement with Sanofi to Develop Atrial Fibrillation Treatment

SAN DIEGO, CA – February 8, 2018 – AnaBios announced today a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target. Through this agreement, AnaBios will acquire development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market, which is estimated to reach $16.17 billion by 2020 according to a recent report by Grand View Research. “Our new partnership with Sanofi, a global healthcare leader, validates the tremendous accomplishments of AnaBios in developing a human tissue- [...]

February 8th, 2018|
Go to Top